BEAM-301: Single dose of BEAM-301 administered by IV
Phase 1/2Recruiting 0 watching 0 views this week💤 Quiet
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glycogen Storage Disease Type Ia
Conditions
Glycogen Storage Disease Type Ia
Trial Timeline
Dec 6, 2024 → Dec 30, 2027
NCT ID
NCT06735755About BEAM-301: Single dose of BEAM-301 administered by IV
BEAM-301: Single dose of BEAM-301 administered by IV is a phase 1/2 stage product being developed by Beam Therapeutics for Glycogen Storage Disease Type Ia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06735755. Target conditions include Glycogen Storage Disease Type Ia.
Hype Score Breakdown
Clinical
13
Activity
8
Company
5
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06735755 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Glycogen Storage Disease Type Ia